Insilico Medicine has reached a historic milestone: the first patient has been dosed with Rentosertib, a drug discovered using generative AI, in a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF). This marks the world's first late-stage human trial of an AI-discovered drug candidate, representing a fundamental shift in how pharmaceutical companies approach drug development.

What Makes This AI Drug Discovery Different?

Rentosertib (also known as ISM001-055) targets a protein called TNIK, which had never before been linked to fibrosis in the lungs. What makes this discovery remarkable is that traditional pharmaceutical researchers would not have identified TNIK as a viable target using conventional methods. The AI system at Insilico Medicine found this connection by analyzing vast amounts of biological data in ways human researchers typically do not.

The drug's journey from AI discovery to human testing has been documented in peer-reviewed scientific journals. In 2024, researchers published the AI-driven discovery process in Nature Biotechnology. A 2025 Nature Medicine study reported promising Phase IIa results showing dose-dependent improvements in lung function. Most recently, a 2026 Nature Biotechnology publication revealed that Rentosertib demonstrated a consistent reduction in biological age across six independent aging clock models.

"TNIK, the target driven by AI, had never previously been linked to fibrosis. This perhaps indicates that AI is carving out a path distinct from traditional research paradigms in target discovery for complex diseases," said Professor Zuojun Xu, Leading Principal Investigator at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.

Professor Zuojun Xu, Leading Principal Investigator, Peking Union Medical College Hospital

How Does This Trial Work and What Are Researchers Testing?

• Trial Design: The GENESIS-IPF-3 study is a prospective, multi-center, randomized, double-blind, placebo-controlled trial enrolling 320 participants across 47 centers in China over 52 weeks of treatment.
• Primary Endpoint: Researchers will measure the annual rate of decline in forced vital capacity (FVC), a standard measure of lung function, to determine whether Rentosertib can slow disease progression.
• Key Secondary Endpoint: The trial will track time to first disease progression event, assessing whether the drug can delay worsening of IPF symptoms in a larger patient population over a longer treatment period than the earlier Phase IIa study.

The trial began at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital on the same day, with leading respiratory medicine experts from the Chinese Academy of Engineering serving as co-investigators.

Why Does This Matter for Patients and the Drug Industry?

Idiopathic pulmonary fibrosis is a severe, progressive lung disease affecting approximately 5 million people worldwide. The median survival for IPF patients is only 3 to 4 years, and current approved treatments can slow disease progression but cannot stop or reverse it. A disease-modifying therapy like Rentosertib, if successful, could represent a significant breakthrough for patients with limited treatment options.

Beyond the immediate patient benefit, this trial demonstrates that AI-driven drug discovery is not just faster but can identify novel therapeutic targets that traditional methods might miss. If Rentosertib succeeds in Phase III, it will validate AI as a legitimate tool for discovering drugs, potentially accelerating the entire pharmaceutical development pipeline.

"I believe Rentosertib will be transformative to patient care in the field of IPF, and AI has enabled this breakthrough with higher speed and reduced cost, which could make a lot of difference in the future of drug discovery," said Carol Satler, Senior Vice President for Clinical Development, Non-Oncology at Insilico Medicine.

Carol Satler, MD, PhD, Senior Vice President for Clinical Development, Non-Oncology, Insilico Medicine

How Is Insilico Medicine Scaling AI Drug Discovery?

Insilico Medicine's commercial success is accelerating its AI research capabilities. The company reported total revenue of approximately $106 million in the first half of 2026, a 287 percent year-over-year increase, and achieved its first profitable half-year since listing with an adjusted net profit exceeding $51 million. This financial momentum is driven by partnerships with major pharmaceutical companies including Eli Lilly, Servier, Takeda, and SK Biopharmaceuticals.

On the research front, Insilico nominated nine development candidates within nine months of 2026 as of late August, setting a new company record for annual pipeline productivity. The company also achieved eight clinical milestones across its proprietary and co-developed programs. To support this expansion, Insilico launched a comprehensive set of benchmarks that allow foundation models to be evaluated across all tasks needed for drug discovery, and released state-of-the-art foundation models that outperform other models and even internal tools in these benchmarks.

The cumulative contract value of Insilico's major collaborations since 2021 has reached approximately $11 billion, with transactions announced in 2026 alone totaling approximately $7.3 billion. This financial backing enables the company to pursue multiple drug candidates simultaneously and invest in AI infrastructure that could reshape how the entire pharmaceutical industry discovers new medicines.

What's the Timeline for Regulatory Approval?

If the Phase III trial succeeds, the path to regulatory approval will take three to four years under favorable conditions, according to the trial's leading investigator. The U.S. Food and Drug Administration granted Orphan Drug Designation to Rentosertib for IPF in February 2023, a status that provides regulatory incentives for drugs treating rare diseases. While Rentosertib remains investigational and has not been approved by any regulatory authority, the milestone of dosing the first Phase III patient represents a critical step toward potential market approval that could benefit IPF patients globally.